Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 3/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24754984 | 1.00 | NPC1 (0.48) | NPC1CTSLCAPN1CTSBCTSS | |
| SCHEMBL25859409 | 0.91 | NPC1 (0.49) | NPC1CTSLCAPN1CTSBCTSS | |
| SCHEMBL30133384 | 0.90 | CTSL (0.56) | NPC1CTSLCAPN1CTSB | |
| SCHEMBL24710299 | 0.90 | CTSL (0.56) | NPC1CTSLCAPN1CTSB | |
| SCHEMBL24754983 | 0.88 | CTSL (0.56) | CTSLCTSBCTSS | |
| SCHEMBL24963709 | 0.87 | CTSL (0.58) | CTSLCTSBCTSS | |
| SCHEMBL30133386 | 0.87 | CTSL (0.48) | NPC1CTSLCAPN1CTSB | |
| SCHEMBL24710297 | 0.87 | CTSL (0.48) | NPC1CTSLCAPN1CTSB | |
| SCHEMBL30133373 | 0.86 | CTSL (0.51) | NPC1CTSLCAPN1CTSB | |
| SCHEMBL24710328 | 0.86 | CTSL (0.51) | NPC1CTSLCAPN1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230033285-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-02-02 | — | — | US | disclosed |
| WO-2022266363-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033285-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | ACE, ACE2, TMPRSS2 | NPC1 792/4885CTSL 19/4885CAPN1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.